OBJECTIVE: In older adults, major depressive disorder (MDD) and chronic low back pain (CLBP) are common and mutually exacerbating. We predicted that duloxetine pharmacotherapy and Depression and Pain Care Management (DPCM) would result in (1) significant improvement in MDD and CLBP and (2) significant improvements in health-related quality of life, anxiety, disability, self-efficacy, and sleep quality. DESIGN AND INTERVENTION: Twelve week open-label study using duloxetine up to 120 mg/day + DPCM. SETTING: Outpatient late-life depression research clinic. PATIENTS: Thirty community-dwelling adults >60 years old. OUTCOME MEASURES: Montgomery Asberg Depression Rating Scale (MADRS) and McGill Pain Questionnaire-Short Form (MPQ-SF). RESULTS: 46.7% (n = 14) of the sample had a depression remission. All subjects who met criteria for the depression remission also had a pain response. 93.3% (n = 28) had a significant pain response. Of the subjects who met criteria for a low back pain response, 50% (n = 14) also met criteria for the depression remission. The mean time to depression remission was 7.6 (SE = 0.6) weeks. The mean time to pain response was 2.8 (SE = 0.5) weeks. There were significant improvements in mental health-related quality of life, anxiety, sleep quality, somatic complaints, and both self-efficacy for pain management and for coping with symptoms. Physical health-related quality of life, back pain-related disability, and self-efficacy for physical functioning did not improve. CONCLUSIONS: Serotonin and norepinephrine reuptake inhibitors like duloxetine delivered with DPCM may be a good choice to treat these linked conditions in older adults. Treatments that target low self-efficacy for physical function and improving disability may further increase response rates.
OBJECTIVE: In older adults, major depressive disorder (MDD) and chronic low back pain (CLBP) are common and mutually exacerbating. We predicted that duloxetine pharmacotherapy and Depression and Pain Care Management (DPCM) would result in (1) significant improvement in MDD and CLBP and (2) significant improvements in health-related quality of life, anxiety, disability, self-efficacy, and sleep quality. DESIGN AND INTERVENTION: Twelve week open-label study using duloxetine up to 120 mg/day + DPCM. SETTING:Outpatientlate-life depression research clinic. PATIENTS: Thirty community-dwelling adults >60 years old. OUTCOME MEASURES: Montgomery Asberg Depression Rating Scale (MADRS) and McGill Pain Questionnaire-Short Form (MPQ-SF). RESULTS: 46.7% (n = 14) of the sample had a depression remission. All subjects who met criteria for the depression remission also had a pain response. 93.3% (n = 28) had a significant pain response. Of the subjects who met criteria for a low back pain response, 50% (n = 14) also met criteria for the depression remission. The mean time to depression remission was 7.6 (SE = 0.6) weeks. The mean time to pain response was 2.8 (SE = 0.5) weeks. There were significant improvements in mental health-related quality of life, anxiety, sleep quality, somatic complaints, and both self-efficacy for pain management and for coping with symptoms. Physical health-related quality of life, back pain-related disability, and self-efficacy for physical functioning did not improve. CONCLUSIONS:Serotonin and norepinephrine reuptake inhibitors like duloxetine delivered with DPCM may be a good choice to treat these linked conditions in older adults. Treatments that target low self-efficacy for physical function and improving disability may further increase response rates.
Authors: E J Lenze; J C Rogers; L M Martire; B H Mulsant; B L Rollman; M A Dew; R Schulz; C F Reynolds Journal: Am J Geriatr Psychiatry Date: 2001 Impact factor: 4.105
Authors: M Carrington Reid; Christianna S Williams; John Concato; Mary E Tinetti; Thomas M Gill Journal: J Am Geriatr Soc Date: 2003-12 Impact factor: 5.562
Authors: Judith A Turner; Deborah Fulton-Kehoe; Gary Franklin; Thomas M Wickizer; Rae Wu Journal: Spine (Phila Pa 1976) Date: 2003-05-15 Impact factor: 3.468
Authors: Martha L Bruce; Thomas R Ten Have; Charles F Reynolds; Ira I Katz; Herbert C Schulberg; Benoit H Mulsant; Gregory K Brown; Gail J McAvay; Jane L Pearson; George S Alexopoulos Journal: JAMA Date: 2004-03-03 Impact factor: 56.272
Authors: Francisco M Kovacs; Alfonso Muriel; María Dolores Castillo Sánchez; José María Medina; Ana Royuela Journal: Spine (Phila Pa 1976) Date: 2007-07-15 Impact factor: 3.468
Authors: Jordan F Karp; Bruce L Rollman; Charles F Reynolds; Jennifer Q Morse; Frank Lotrich; Sati Mazumdar; Natalia Morone; Debra K Weiner Journal: Pain Med Date: 2012-02-07 Impact factor: 3.750
Authors: Howard J Aizenstein; Carmen Andreescu; Kathryn L Edelman; Jennifer L Cochran; Julie Price; Meryl A Butters; Jordan Karp; Meenal Patel; Charles F Reynolds Journal: Am J Psychiatry Date: 2011-07-28 Impact factor: 18.112
Authors: Carmen Andreescu; Dana L Tudorascu; Meryl A Butters; Erica Tamburo; Meenal Patel; Julie Price; Jordan F Karp; Charles F Reynolds; Howard Aizenstein Journal: Psychiatry Res Date: 2013-10-18 Impact factor: 3.222
Authors: Joseph A Carley; Jordan F Karp; Angela Gentili; Zachary A Marcum; M Carrington Reid; Eric Rodriguez; Michelle I Rossi; Joseph Shega; Stephen Thielke; Debra K Weiner Journal: Pain Med Date: 2015-11-05 Impact factor: 3.750